{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:18:35Z","timestamp":1792801115151,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Instituto de Salud Carlos III through the R\u00edo Hortega Fellowship","award":["CM21\/00243"],"award-info":[{"award-number":["CM21\/00243"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III through the R\u00edo Hortega Fellowship","award":["CM22\/00052"],"award-info":[{"award-number":["CM22\/00052"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III through the R\u00edo Hortega Fellowship","award":["CM22\/00219"],"award-info":[{"award-number":["CM22\/00219"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III through the R\u00edo Hortega Fellowship","award":["CM23\/00291"],"award-info":[{"award-number":["CM23\/00291"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III through the R\u00edo Hortega Fellowship","award":["CM23\/00176"],"award-info":[{"award-number":["CM23\/00176"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer\u2019s Association","doi-asserted-by":"crossref","award":["AARG-22-973966"],"award-info":[{"award-number":["AARG-22-973966"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100015442","name":"Global Brain Health Institute","doi-asserted-by":"publisher","award":["GBHI_ALZ-18-543740"],"award-info":[{"award-number":["GBHI_ALZ-18-543740"]}],"id":[{"id":"10.13039\/100015442","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Societat Catalana de Neurologia","award":["Premi Beca Fundaci\u00f3 SCN 2020"],"award-info":[{"award-number":["Premi Beca Fundaci\u00f3 SCN 2020"]}]},{"name":"Fondo Investigaciones Sanitario (FIS), Instituto de Salud Carlos III","award":["PI21\/00791, PI14\/01126, PI17\/01019, PI20\/01473, PI13\/01532, PI16\/01825, PI18\/00335, PI22\/00785, PI19\/00882, PI18\/00435, PI21\/00791, PI22\/00611, INT19\/00016, INT23\/00048, PI17\/01896, PI24\/00598 and AC19\/00103"],"award-info":[{"award-number":["PI21\/00791, PI14\/01126, PI17\/01019, PI20\/01473, PI13\/01532, PI16\/01825, PI18\/00335, PI22\/00785, PI19\/00882, PI18\/00435, PI21\/00791, PI22\/00611, INT19\/00016, INT23\/00048, PI17\/01896, PI24\/00598 and AC19\/00103"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Fondo Investigaciones Sanitario (FIS), Instituto de Salud Carlos III","award":["PI21\/00791, PI14\/01126, PI17\/01019, PI20\/01473, PI13\/01532, PI16\/01825, PI18\/00335, PI22\/00785, PI19\/00882, PI18\/00435, PI21\/00791, PI22\/00611, INT19\/00016, INT23\/00048, PI17\/01896, PI24\/00598 and AC19\/00103"],"award-info":[{"award-number":["PI21\/00791, PI14\/01126, PI17\/01019, PI20\/01473, PI13\/01532, PI16\/01825, PI18\/00335, PI22\/00785, PI19\/00882, PI18\/00435, PI21\/00791, PI22\/00611, INT19\/00016, INT23\/00048, PI17\/01896, PI24\/00598 and AC19\/00103"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Fondo Investigaciones Sanitario (FIS), Instituto de Salud Carlos III","award":["PI21\/00791, PI14\/01126, PI17\/01019, PI20\/01473, PI13\/01532, PI16\/01825, PI18\/00335, PI22\/00785, PI19\/00882, PI18\/00435, PI21\/00791, PI22\/00611, INT19\/00016, INT23\/00048, PI17\/01896, PI24\/00598 and AC19\/00103"],"award-info":[{"award-number":["PI21\/00791, PI14\/01126, PI17\/01019, PI20\/01473, PI13\/01532, PI16\/01825, PI18\/00335, PI22\/00785, PI19\/00882, PI18\/00435, PI21\/00791, PI22\/00611, INT19\/00016, INT23\/00048, PI17\/01896, PI24\/00598 and AC19\/00103"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Fondo Investigaciones Sanitario (FIS), Instituto de Salud Carlos III","award":["PI21\/00791, PI14\/01126, PI17\/01019, PI20\/01473, PI13\/01532, PI16\/01825, PI18\/00335, PI22\/00785, PI19\/00882, PI18\/00435, PI21\/00791, PI22\/00611, INT19\/00016, INT23\/00048, PI17\/01896, PI24\/00598 and AC19\/00103"],"award-info":[{"award-number":["PI21\/00791, PI14\/01126, PI17\/01019, PI20\/01473, PI13\/01532, PI16\/01825, PI18\/00335, PI22\/00785, PI19\/00882, PI18\/00435, PI21\/00791, PI22\/00611, INT19\/00016, INT23\/00048, PI17\/01896, PI24\/00598 and AC19\/00103"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Fondo Investigaciones Sanitario (FIS), Instituto de Salud Carlos III","award":["PI21\/00791, PI14\/01126, PI17\/01019, PI20\/01473, PI13\/01532, PI16\/01825, PI18\/00335, PI22\/00785, PI19\/00882, PI18\/00435, PI21\/00791, PI22\/00611, INT19\/00016, INT23\/00048, PI17\/01896, PI24\/00598 and AC19\/00103"],"award-info":[{"award-number":["PI21\/00791, PI14\/01126, PI17\/01019, PI20\/01473, PI13\/01532, PI16\/01825, PI18\/00335, PI22\/00785, PI19\/00882, PI18\/00435, PI21\/00791, PI22\/00611, INT19\/00016, INT23\/00048, PI17\/01896, PI24\/00598 and AC19\/00103"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["1R01AG056850-01A1; R21AG056974; and R01AG061566"],"award-info":[{"award-number":["1R01AG056850-01A1; R21AG056974; and R01AG061566"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["1R01AG056850-01A1; R21AG056974; and R01AG061566"],"award-info":[{"award-number":["1R01AG056850-01A1; R21AG056974; and R01AG061566"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["1R01AG056850-01A1; R21AG056974; and R01AG061566"],"award-info":[{"award-number":["1R01AG056850-01A1; R21AG056974; and R01AG061566"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CIBERNED program","award":["Program 1, Alzheimer Disease"],"award-info":[{"award-number":["Program 1, Alzheimer Disease"]}]},{"name":"CIBERNED program","award":["Program 1, Alzheimer Disease"],"award-info":[{"award-number":["Program 1, Alzheimer Disease"]}]},{"name":"Fondo Europeo de Desarrollo Regional, Unio\u0301n Europea, \u201cUna manera de hacer Europa"},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"crossref","award":["2017-SGR-547, SLT006\/17\/125, SLT006\/17\/119, SLT002\/16\/408"],"award-info":[{"award-number":["2017-SGR-547, SLT006\/17\/125, SLT006\/17\/119, SLT002\/16\/408"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"crossref","award":["2017-SGR-547, SLT006\/17\/125, SLT006\/17\/119, SLT002\/16\/408"],"award-info":[{"award-number":["2017-SGR-547, SLT006\/17\/125, SLT006\/17\/119, SLT002\/16\/408"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fundaci\u00f3 Bancaria La Caixa"},{"name":"Fundaci\u00f3 Catalana S\u00edndrome de Down"},{"DOI":"10.13039\/501100001673","name":"J\u00e9r\u00f4me Lejeune Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001673","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["INT21\/00073, PI20\/01473 and PI23\/01786"],"award-info":[{"award-number":["INT21\/00073, PI20\/01473 and PI23\/01786"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health grants","doi-asserted-by":"crossref","award":["R01 AG056850; R21 AG056974, R01 AG061566, R01 AG081394 and R61AG066543 and 1RF1AG080769-01"],"award-info":[{"award-number":["R01 AG056850; R21 AG056974, R01 AG061566, R01 AG081394 and R61AG066543 and 1RF1AG080769-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010805","name":"Fundaci\u00f3n Tatiana P\u00e9rez de Guzm\u00e1n el Bueno","doi-asserted-by":"publisher","award":["IIBSP-DOW-2020-151"],"award-info":[{"award-number":["IIBSP-DOW-2020-151"]}],"id":[{"id":"10.13039\/501100010805","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Horizon 2020\u2013Research and Innovation Framework Programme from the European Union","award":["H2020-SC1-BHC-2018-2020"],"award-info":[{"award-number":["H2020-SC1-BHC-2018-2020"]}],"id":[{"id":"https:\/\/ror.org\/019w4f821","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006312","name":"Brightfocus","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006312","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Life Molecular Imaging"},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","award":["20141210, 044412 and 20142610"],"award-info":[{"award-number":["20141210, 044412 and 20142610"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Knowledge on the effect of analytical variability and storage conditions are essential for the successful implementation of plasma pTau\n                      <jats:sub>217<\/jats:sub>\n                      in prospective settings.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      To investigate the performance of plasma pTau\n                      <jats:sub>217<\/jats:sub>\n                      , measured in consecutive samples with LUMIPULSE, for detecting Alzheimer\u2019s disease in a prospective memory clinic setting, along with evaluating its pre-analytical and analytical stability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We prospectively measured pTau\n                      <jats:sub>217<\/jats:sub>\n                      using the LUMIPULSE automated platform in consecutive patient plasma samples collected between May and November 2024 at the Sant Pau Memory Unit (Barcelona). A subset of participants also underwent paired lumbar puncture for CSF AD biomarkers. We compared biomarker concentrations under different short-term storage conditions (4\u00baC vs -20\u00baC) and different protocol pipelines, and assessed lot-to-lot variability. In the subset with available CSF biomarkers, logistic regression was used to evaluate the association between plasma pTau217 and the likelihood of a positive (A\u2009+) or a negative (A-) CSF amyloid status. Using ROC analysis, in this prospective cohort we evaluated the accuracy of previously established thresholds derived from historical samples.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 280 participants, divided into two groups: those with (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009109) and without CSF data (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009171). Among the subset with CSF, 48% were A\u2009+\u2009, with a plasma pTau\n                      <jats:sub>217<\/jats:sub>\n                      fold-change of 4.5\u2009\u00d7\u2009compared to A-. We found no differences in plasma pTau\n                      <jats:sub>217<\/jats:sub>\n                      concentrations between either short-term storage conditions. The overall coefficients of analytical variation ranged from 1.8% to 3.2%. Plasma pTau\n                      <jats:sub>217<\/jats:sub>\n                      concentrations were slightly higher in paired samples of the clinical protocol. Following a two-threshold approach, the need of confirmatory tests (grey zones) after measuring plasma pTau\n                      <jats:sub>217<\/jats:sub>\n                      ranged between 45.9% and 18.3% using our previously reported strict or lenient cutoffs (overall accuracy 96.6% and 92.1%, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The robust stability and low lot-to-lot variability of plasma pTau\n                      <jats:sub>217<\/jats:sub>\n                      measurement in an automated platform result in high diagnostic performance of this biomarker in the prospective evaluation of patients in a memory clinic setting. These findings support its implementation into clinical routine, offering clinicians an accessible biomarker for AD diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-025-01779-7","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T01:58:57Z","timestamp":1751680737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer\u2019s disease in a tertiary memory clinic"],"prefix":"10.1186","volume":"17","author":[{"given":"Javier","family":"Arranz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuole","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rubio-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00cd\u00f1igo","family":"Rodr\u00edguez-Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Enrique","family":"Arriola-Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Maure-Blesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Garcia-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Selma-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Carmona-Iragui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Barroeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Ill\u00e1n-Gala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Santos-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Fortea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Lle\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Tondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Alcolea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"issue":"8","key":"1779_CR1","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of alzheimer\u2019s disease: alzheimer\u2019s association workgroup. Alzheimer\u2019s and Dementia. 2024;20(8):5143\u201369.","journal-title":"Alzheimer\u2019s and Dementia"},{"key":"1779_CR2","doi-asserted-by":"crossref","unstructured":"Dubois B, Villain N, Schneider L, Fox N, Campbell N, Galasko D, et al. Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation. JAMA Neurol. 2024; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39483064","DOI":"10.1001\/jamaneurol.2024.3770"},{"key":"1779_CR3","doi-asserted-by":"crossref","unstructured":"Schindler SE, Atri A. The role of cerebrospinal fluid and other biomarker modalities in the Alzheimer\u2019s disease diagnostic revolution. Vol. 3, Nature Aging. Springer; 2023. p. 460\u20132.","DOI":"10.1038\/s43587-023-00400-6"},{"key":"1779_CR4","doi-asserted-by":"crossref","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Vol. 27, Nature Medicine. Nature Research; 2021. p. 954\u201363.","DOI":"10.1038\/s41591-021-01382-x"},{"key":"1779_CR5","doi-asserted-by":"crossref","unstructured":"Hampel H, Hu Y, Cummings J, Mattke S, Iwatsubo T, Nakamura A, et al. Blood-based biomarkers for Alzheimer\u2019s disease: Current state and future use in a transformed global healthcare landscape. Vol. 111, Neuron. Cell Press; 2023. p. 2781\u201399.","DOI":"10.1016\/j.neuron.2023.05.017"},{"issue":"1","key":"1779_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13195-024-01513-9","volume":"16","author":"J Arranz","year":"2024","unstructured":"Arranz J, Zhu N, Rubio-Guerra S, Rodr\u00edguez-Baz \u00cd, Ferrer R, Carmona-Iragui M, et al. Diagnostic performance of plasma pTau217, pTau181, A\u03b21\u201342 and A\u03b21\u201340 in the LUMIPULSE automated platform for the detection of Alzheimer disease. Alzheimers Res Ther. 2024;16(1):139.","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"1779_CR7","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. discriminative accuracy of plasma phospho-tau217 for alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772\u201381.","journal-title":"JAMA"},{"issue":"4","key":"1779_CR8","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/alz.12751","volume":"19","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist S, Stomrud E, Cullen N, Janelidze S, Manuilova E, Jethwa A, et al. An accurate fully automated panel of plasma biomarkers for Alzheimer\u2019s disease. Alzheimer\u2019s and Dementia. 2023;19(4):1204\u201315.","journal-title":"Alzheimer\u2019s and Dementia"},{"issue":"2","key":"1779_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, et al. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs Tau positron emission tomography. JAMA Neurol. 2023;80(2):188\u201399.","journal-title":"JAMA Neurol"},{"key":"1779_CR10","doi-asserted-by":"crossref","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonatis E, et al. Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer\u2019s disease pathology. medRxiv. 2023; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37502842","DOI":"10.1101\/2023.07.11.23292493"},{"issue":"2","key":"1779_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2021.4654","volume":"79","author":"A Leuzy","year":"2022","unstructured":"Leuzy A, Smith R, Cullen NC, Strandberg O, Vogel JW, Binette AP, et al. Biomarker-based prediction of longitudinal tau positron emission tomography in Alzheimer disease. JAMA Neurol. 2022;79(2):149\u201358.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1779_CR12","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barth\u00e9lemy","year":"2024","unstructured":"Barth\u00e9lemy NR, Salvad\u00f3 G, Schindler SE, He Y, Janelidze S, Collij LE, et al. Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med. 2024;30(4):1085\u201395.","journal-title":"Nat Med"},{"key":"1779_CR13","doi-asserted-by":"crossref","unstructured":"Teunissen CE, Thijssen EH. Plasma p-tau217: From \u201cnew kid\u201d to most promising candidate for Alzheimer\u2019s disease blood test. Vol. 143, Brain. Oxford University Press; 2020. p. 3170\u201380.","DOI":"10.1093\/brain\/awaa329"},{"issue":"11","key":"1779_CR14","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1002\/alz.13026","volume":"19","author":"J Therriault","year":"2023","unstructured":"Therriault J, Servaes S, Tissot C, Rahmouni N, Ashton NJ, Benedet AL, et al. Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement. 2023;19(11):4967\u201377.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"1779_CR15","first-page":"1797","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0 M, Ashton NJ, Shekari M, Salvad\u00f3 G, Ortiz-Romero P, Montoliu-Gaya L, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2022;28(9):1797\u2013801.","journal-title":"Nat Med"},{"issue":"9","key":"1779_CR16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum WS, Cullen NC, Janelidze S, Ashton NJ, Zimmer ER, Therriault J, et al. A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat Aging. 2023;3(9):1079\u201390.","journal-title":"Nat Aging"},{"key":"1779_CR17","doi-asserted-by":"crossref","unstructured":"Janelidze S, Bali D, Ashton NJ, Barth\u00e9lemy NR, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain. 2022 Sep 10;","DOI":"10.1093\/brain\/awac333"},{"key":"1779_CR18","doi-asserted-by":"crossref","unstructured":"Ashton NJ, Puig-Pijoan A, Mil\u00e0-Alom\u00e0 M, Fern\u00e1ndez-Lebrero A, Garc\u00eda-Escobar G, Gonz\u00e1lez-Ortiz F, et al. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement. 2022;","DOI":"10.1002\/alz.12841"},{"key":"1779_CR19","doi-asserted-by":"publisher","unstructured":"Selma-Gonzalez J, Rubio-Guerra S, Garc\u00eda-Castro J, Vera-Campuzano E, Sala I, S\u00e1nchez-Saudin\u00f3s MB et al. Association of Plasma Phosphorylated Tau 217 With Clinical Deterioration Across Alzheimer Disease Stages. Neurology. 2025 Jul;105(1):e213769. https:\/\/doi.org\/10.1212\/WNL.0000000000213769. Epub 2025 Jun 5. PMID: 40472304.","DOI":"10.1212\/WNL.0000000000213769"},{"issue":"2","key":"1779_CR20","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/alz.13525","volume":"20","author":"F Gonzalez-Ortiz","year":"2024","unstructured":"Gonzalez-Ortiz F, Ferreira PCL, Gonz\u00e1lez-Escalante A, Montoliu-Gaya L, Ortiz-Romero P, Kac PR, et al. A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer\u2019s disease. Alzheimer\u2019s and Dementia. 2024;20(2):1239\u201349.","journal-title":"Alzheimer\u2019s and Dementia"},{"issue":"1","key":"1779_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13195-022-01005-8","volume":"14","author":"C Groot","year":"2022","unstructured":"Groot C, Cicognola C, Bali D, Triana-Baltzer G, Dage JL, Pontecorvo MJ, et al. Diagnostic and prognostic performance to detect Alzheimer\u2019s disease and clinical progression of a novel assay for plasma p-tau217. Alzheimers Res Ther. 2022;14(1):67.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1779_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-021-00939-9","volume":"13","author":"S Bayoumy","year":"2021","unstructured":"Bayoumy S, Verberk IMW, den Dulk B, Hussainali Z, Zwan M, van der Flier WM, et al. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimers Res Ther. 2021;13(1):1\u20135.","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"1779_CR23","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","volume":"78","author":"MM Mielke","year":"2021","unstructured":"Mielke MM, Frank RD, Dage JL, Jeromin A, Ashton NJ, Blennow K, et al. Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol. 2021;78(9):1108\u201317.","journal-title":"JAMA Neurol"},{"key":"1779_CR24","first-page":"102","volume":"1","author":"J Therriault","year":"2024","unstructured":"Therriault J, Ashton NJ, Pola I, Triana-Baltzer G, Brum WS, Di Molfetta G, et al. Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer\u2019s pathology. EBioMedicine. 2024;1:102.","journal-title":"EBioMedicine"},{"issue":"1","key":"1779_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41598-024-51334-x","volume":"14","author":"P Kivis\u00e4kk","year":"2024","unstructured":"Kivis\u00e4kk P, Fatima HA, Cahoon DS, Otieno B, Chacko L, Minooei F, et al. Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer\u2019s disease. Sci Rep. 2024;14(1):629.","journal-title":"Sci Rep"},{"key":"1779_CR26","doi-asserted-by":"publisher","unstructured":"Pilotto A, Quaresima V, Trasciatti C, Tolassi C, Bertoli D, Mordenti C, et al. Plasma p-tau217 in Alzheimer\u2019s disease: Lumipulse and ALZpath SIMOA head-to-head comparison. Brain. 2024 Dec 16; Available from: https:\/\/academic.oup.com\/brain\/advance-article\/doi\/https:\/\/doi.org\/10.1093\/brain\/awae368\/7921772","DOI":"10.1093\/brain\/awae368\/7921772"},{"key":"1779_CR27","doi-asserted-by":"crossref","unstructured":"Ashton NJ, Keshavan A, Brum WS, Andreasson U, Arslan B, Droescher M, et al. The Alzheimers Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study. medRxiv. 2024 Aug 22; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39228740","DOI":"10.1101\/2024.08.22.24312244"},{"key":"1779_CR28","doi-asserted-by":"crossref","unstructured":"Feizpour A, Doecke JD, Dor\u00e9 V, Krishnadas N, Huang K, Bourgeat P, et al. Detection and staging of Alzheimer\u2019s disease by plasma pTau217 on a high throughput immunoassay platform. 2024. Available from: www.thelancet.com","DOI":"10.2139\/ssrn.4771390"},{"key":"1779_CR29","doi-asserted-by":"crossref","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Vol. 21, The Lancet Neurology. Elsevier Ltd; 2022. p. 66\u201377.","DOI":"10.1016\/S1474-4422(21)00361-6"},{"key":"1779_CR30","doi-asserted-by":"crossref","unstructured":"Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Vol. 18, Alzheimer\u2019s and Dementia. John Wiley and Sons Inc; 2022. p. 2669\u201386.","DOI":"10.1002\/alz.12756"},{"key":"1779_CR31","unstructured":"Su\u00e1rez-Calvet M, Abdelnour C, Alcolea D, Mendi\u00f3roz-Iriarte M, Balasa M, Morenas-Rodr\u00edguez E, et al. Blood-based biomarkers for Alzheimer\u2019s disease: Positioning document and usage recommendations from the Behavioral Neurology and Dementia Study Group of the Spanish Society of Neurology. Neurologia. 2024;"},{"key":"1779_CR32","doi-asserted-by":"crossref","unstructured":"Sch\u00f6ll M, Verberk IMW, del Campo M, Delaby C, Therriault J, Chong JR, et al. Challenges in the practical implementation of blood biomarkers for Alzheimer\u2019s disease. Vol. 5, The Lancet Healthy Longevity. Elsevier Ltd; 2024.","DOI":"10.1016\/j.lanhl.2024.07.013"},{"key":"1779_CR33","doi-asserted-by":"crossref","unstructured":"Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Vol. 18, Alzheimer\u2019s and Dementia. John Wiley and Sons Inc; 2022. p. 2669\u201386.","DOI":"10.1002\/alz.12756"},{"issue":"7","key":"1779_CR34","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler SE, Galasko D, Pereira AC, Rabinovici GD, Salloway S, Su\u00e1rez-Calvet M, et al. Acceptable performance of blood biomarker tests of amyloid pathology \u2014 recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease. Nat Rev Neurol. 2024;20(7):426\u201339.","journal-title":"Nat Rev Neurol"},{"key":"1779_CR35","doi-asserted-by":"publisher","unstructured":"Alcolea D, Beeri MS, Rojas JC, Gardner RC, Lle\u00f3 A. Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist. Neurology. 2023;https:\/\/doi.org\/10.1212\/WNL.0000000000207193. Available from: http:\/\/www.neurology.org\/lookup\/doi\/https:\/\/doi.org\/10.1212\/WNL.0000000000207193","DOI":"10.1212\/WNL.0000000000207193"},{"issue":"9","key":"1779_CR36","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1515\/cclm-2023-0245","volume":"61","author":"A Mansilla","year":"2023","unstructured":"Mansilla A, Canyelles M, Ferrer R, Arranz J, Rodr\u00edguez-Baz \u00cd, Zhu N, et al. Effects of storage conditions on the stability of blood-based markers for the diagnosis of Alzheimer\u2019s disease. Clin Chem Lab Med. 2023;61(9):1580\u20139.","journal-title":"Clin Chem Lab Med"},{"key":"1779_CR37","doi-asserted-by":"crossref","unstructured":"Musso G, Cosma C, Zaninotto M, Gabelli C, Basso D, Plebani M. Pre-analytical variability of the Lumipulse immunoassay for plasma biomarkers of Alzheimer\u2019s disease. Vol. 61, Clinical Chemistry and Laboratory Medicine. De Gruyter Open Ltd; 2023. p. E53\u20136.","DOI":"10.1515\/cclm-2022-0770"},{"issue":"3","key":"1779_CR38","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/alz.12706","volume":"19","author":"NC Cullen","year":"2023","unstructured":"Cullen NC, Janelidze S, Mattsson-Carlgren N, Palmqvist S, Bittner T, Suridjan I, et al. Test-retest variability of plasma biomarkers in Alzheimer\u2019s disease and its effects on clinical prediction models. Alzheimer\u2019s Dementia. 2023;19(3):797\u2013806.","journal-title":"Alzheimer\u2019s Dementia"},{"issue":"5","key":"1779_CR39","first-page":"597","volume":"1","author":"D Alcolea","year":"2019","unstructured":"Alcolea D, Clarim\u00f3n J, Carmona-Iragui M, Ill\u00e1n-Gala I, Morenas-Rodr\u00edguez E, Barroeta I, et al. The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimers Dement. 2019;1(5):597\u2013609.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"1779_CR40","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/acn3.50873","volume":"6","author":"D Alcolea","year":"2019","unstructured":"Alcolea D, Pegueroles J, Mu\u00f1oz L, Camacho V, L\u00f3pez-Mora D, Fern\u00e1ndez-Le\u00f3n A, et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer\u2019s disease on Lumipulse. Ann Clin Transl Neurol. 2019;6(9):1815\u201324.","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"1779_CR41","doi-asserted-by":"publisher","first-page":"6739","DOI":"10.1007\/s00415-024-12631-7","volume":"271","author":"G Cecchetti","year":"2024","unstructured":"Cecchetti G, Agosta F, Rugarli G, Spinelli EG, Ghirelli A, Zavarella M, et al. Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer\u2019s disease: a real-world study. J Neurol. 2024;271(10):6739\u201349.","journal-title":"J Neurol"},{"key":"1779_CR42","doi-asserted-by":"crossref","unstructured":"Eastwood SM, Meyer MR, Kirmess KM, Wente-Roth TL, Irvin F, Holubasch MS, et al. PrecivityAD2TM Blood Test: Analytical Validation of an LC-MS\/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-\u03b242\/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology. Diagnostics. 2024;14(16).","DOI":"10.3390\/diagnostics14161739"},{"key":"1779_CR43","doi-asserted-by":"crossref","unstructured":"Sch\u00f6ll M, Verberk IMW, del Campo M, Delaby C, Therriault J, Chong JR, et al. Challenges in the practical implementation of blood biomarkers for Alzheimer\u2019s disease. Vol. 5, The Lancet Healthy Longevity. Elsevier Ltd; 2024.","DOI":"10.1016\/j.lanhl.2024.07.013"},{"issue":"6","key":"1779_CR44","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/alz.12466","volume":"18","author":"JA Syrjanen","year":"2022","unstructured":"Syrjanen JA, Campbell MR, Algeciras-Schimnich A, Vemuri P, Graff-Radford J, Machulda MM, et al. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimer\u2019s and Dementia. 2022;18(6):1128\u201340.","journal-title":"Alzheimer\u2019s and Dementia"},{"key":"1779_CR45","doi-asserted-by":"crossref","unstructured":"Therriault J, Janelidze S, Benedet AL, Ashton NJ, Arranz Mart\u00ednez J, Gonzalez-Escalante A, et al. Diagnosis of Alzheimer\u2019s disease using plasma biomarkers adjusted to clinical probability. Nat Aging. 2024;4(11):1529\u201337. Available from: https:\/\/www.nature.com\/articles\/s43587-024-00731-y","DOI":"10.1038\/s43587-024-00731-y"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01779-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01779-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01779-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T01:59:05Z","timestamp":1751680745000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01779-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1779"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01779-7","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,5]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.A. participated in advisory boards from Fujirebio-Europe, Roche Diagnostics, Grifols S.A. and Lilly, and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmac\u00e9utica S.L., Zambon S.A.U., Neuraxpharm, Alter Medica, Lilly and Esteve Pharmaceuticals S.A. D.A. declares a filed patent application (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease). JA reported receiving personal fees for service on educational activities from Lilly, Esteve, Fujirebio-Europe and Roche diagnostics. S.R.-G. received honoraria from Esteve Pharmaceuticals S.A. for educational activities AL declare a filed patent application (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease). AL has served as a consultant or on advisory boards for Almirall, Fujirebio-Europe, Roche, Biogen, Grifols, Novartis, Eisai, Lilly, and Nutricia, outside the submitted work. JF reported serving on the advisory boards, adjudication committees, or speaker honoraria from AC Immune, Adamed, Alzheon, Biogen, Eisai, Esteve, Fujirebio, Ionis, Laboratorios Carnot, Life Molecular Imaging, Lilly, Lundbeck, Novo Nordisk, Perha, Roche, Zamb\u00f3n, Spanish Neurological Society, T21 Research Society, Lumind foundation, J\u00e9r\u00f4me-Lejeune Foundation, Alzheimer\u2019s Association, National Institutes of Health USA, and Instituto de Salud Carlos III. JF reports holding a patent for markers of synaptopathy in neurodegenerative disease (licensed to ADx, EPI8382175.0). No other competing interests were reported. MCI participated in an advisory board from Roche Diagnostics an dreceived speaker honoraria from Roche Diagnostics, Neuraxpharm, Lilly, Esteve Pharmaceuticals S.A and Adium Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}